JPH11199426A - Cosmetic - Google Patents
CosmeticInfo
- Publication number
- JPH11199426A JPH11199426A JP19398A JP19398A JPH11199426A JP H11199426 A JPH11199426 A JP H11199426A JP 19398 A JP19398 A JP 19398A JP 19398 A JP19398 A JP 19398A JP H11199426 A JPH11199426 A JP H11199426A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- agent
- skin
- cosmetic
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 33
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical group C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims abstract description 27
- 150000000996 L-ascorbic acids Chemical class 0.000 claims abstract description 16
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 13
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 10
- 229960003720 enoxolone Drugs 0.000 claims abstract description 10
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- -1 ethyl ascorbic acid Chemical compound 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 11
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 238000003860 storage Methods 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 206010013786 Dry skin Diseases 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 4
- 230000002421 anti-septic effect Effects 0.000 abstract description 4
- 150000005846 sugar alcohols Polymers 0.000 abstract description 4
- 229940088594 vitamin Drugs 0.000 abstract description 4
- 229930003231 vitamin Natural products 0.000 abstract description 4
- 235000013343 vitamin Nutrition 0.000 abstract description 4
- 239000011782 vitamin Substances 0.000 abstract description 4
- 239000002738 chelating agent Substances 0.000 abstract description 3
- 239000003995 emulsifying agent Substances 0.000 abstract description 3
- 239000003002 pH adjusting agent Substances 0.000 abstract description 3
- 239000002304 perfume Substances 0.000 abstract description 3
- 239000000049 pigment Substances 0.000 abstract description 2
- 239000000419 plant extract Substances 0.000 abstract description 2
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 239000002562 thickening agent Substances 0.000 abstract description 2
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 abstract 1
- 239000002250 absorbent Substances 0.000 abstract 1
- 230000002745 absorbent Effects 0.000 abstract 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 238000000149 argon plasma sintering Methods 0.000 abstract 1
- 238000004061 bleaching Methods 0.000 abstract 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 27
- 239000000194 fatty acid Substances 0.000 description 11
- 230000002087 whitening effect Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940120145 3-o-ethylascorbic acid Drugs 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 229960005150 glycerol Drugs 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 229940092738 beeswax Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- ZLSFWAPBBIIMKI-KVINTPOGSA-M dipotassium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxido-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [K+].[K+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H]([O-])C1(C)C ZLSFWAPBBIIMKI-KVINTPOGSA-M 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- LRZBIPQJHILPJI-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-(2,3-dihydroxypropyl)octadecanoate Chemical compound CCCCCCCCCCCCCCCCC(CC(O)CO)C(=O)OCC(O)CO LRZBIPQJHILPJI-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- ZCOLQXXFCPFSNU-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]ethanesulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCC(=O)N(C)CCS(O)(=O)=O ZCOLQXXFCPFSNU-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- JLQJZRLUCHOZHX-RXSVEWSESA-N S(=O)(=O)(O)OS(=O)(=O)O.O=C1C(O)=C(O)[C@H](O1)[C@@H](O)CO Chemical compound S(=O)(=O)(O)OS(=O)(=O)O.O=C1C(O)=C(O)[C@H](O1)[C@@H](O)CO JLQJZRLUCHOZHX-RXSVEWSESA-N 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QDWKGBODFCIIJK-IHMBCTQLSA-N azanium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [NH4+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C QDWKGBODFCIIJK-IHMBCTQLSA-N 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- WODOUQLMOIMKAL-FJSYBICCSA-L disodium;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O WODOUQLMOIMKAL-FJSYBICCSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- YRIUSKIDOIARQF-UHFFFAOYSA-N dodecyl benzenesulfonate Chemical compound CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 YRIUSKIDOIARQF-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940071161 dodecylbenzenesulfonate Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は化粧料に関し、さら
に詳しくは、皮膚に対して優れた美白効果と抗炎症効果
を有し、肌荒れを抑制するとともに、保存安定性や皮膚
安全性にも優れる皮膚用化粧料に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to cosmetics, and more particularly to cosmetics, which have excellent whitening and anti-inflammatory effects on the skin, suppress rough skin, and have excellent storage stability and skin safety. The present invention relates to skin cosmetics.
【0002】[0002]
【従来の技術】近年、皮膚科学の進歩により、様々な生
体メカニズムが解明されてきた。例えば、皮膚組織が紫
外線などの外的刺激を受けると、該組織中にアラキドン
酸が産生され、さらにその代謝産物であるロイコトリエ
ン類や、プロスタグランジン類が産生する。これらの代
謝産物は、肌荒れなどの皮膚組織に傷害を与える。さら
に、上記のロイコトリエン類やプロスタグランジン類お
よび炎症時に肥満細胞から遊離されるヒスタミンは、メ
ラノサイトに働きかけ、その活性を促進し、炎症部位で
色素沈着をもたらし、シミや色黒の原因となっている。2. Description of the Related Art In recent years, various biological mechanisms have been elucidated with the progress of dermatology. For example, when skin tissue is subjected to an external stimulus such as ultraviolet light, arachidonic acid is produced in the tissue, and leukotrienes and prostaglandins, which are metabolites thereof, are produced. These metabolites damage skin tissues such as rough skin. Furthermore, the above-mentioned leukotrienes and prostaglandins and histamine released from mast cells during inflammation act on melanocytes, promoting their activity, causing pigmentation at sites of inflammation, causing spots and darkening. I have.
【0003】従来、紫外線などによって引き起こされる
皮膚の肌荒れ防止には、抗炎症剤であるグリチルレチン
酸やその誘導体(以下、グリチルレチン類と称すことが
ある。)が使用されてきた。このグリチルレチン類は、
紫外線などの外的刺激を受けて皮膚組織中に生じるアラ
キドン酸の産生を抑制する作用を有しており、その結
果、アラキドン酸の代謝産物であるロイコトリエン類や
プロスタグランジン類の産生が抑制されるので、それら
の代謝産物によって引き起こされる皮膚組織の傷害を予
防するものである。しかしながら、グリチルレチン類だ
けでは紫外線などによって引き起こされる皮膚の肌荒れ
後の色素沈着によるシミや色黒の防止には、充分な効果
が望めないという問題があった。Hitherto, glycyrrhetinic acid and its derivatives (hereinafter, sometimes referred to as glycyrrhetins), which are anti-inflammatory agents, have been used to prevent rough skin caused by ultraviolet rays or the like. This glycyrrhetin,
It has the effect of suppressing the production of arachidonic acid generated in skin tissue in response to external stimuli such as ultraviolet rays, and as a result, the production of metabolites of arachidonic acid, leukotrienes and prostaglandins, is suppressed. Therefore, it is intended to prevent skin tissue damage caused by those metabolites. However, glycyrrhetins alone have a problem that a sufficient effect cannot be expected in preventing spots and darkness due to pigmentation after rough skin caused by ultraviolet rays or the like.
【0004】従来、このような問題を改善するために、
L−アスコルビン酸、グルタチオン、コロイドイオウな
どが使用されていた。しかしながら、L−アスコルビン
酸は、それ自体が酸化されやすいため、効果を充分に発
揮しにくい上、それを配合した化粧料が経時により、変
色や変臭するなどの欠点があった。また、グルタチオン
やコロイドイオウは特有の臭気や安定性に問題があり、
製品化に支障があった。Conventionally, in order to improve such a problem,
L-ascorbic acid, glutathione, colloidal sulfur and the like have been used. However, since L-ascorbic acid itself is easily oxidized, it is difficult to sufficiently exert its effect, and the cosmetics containing the same have disadvantages such as discoloration and odor over time. In addition, glutathione and colloidal sulfur have a problem in peculiar odor and stability,
There was a hindrance to commercialization.
【0005】一方、ステロイド剤は、充分な抗炎症効果
を発揮するが、連用後に、リバウンド現象が起こり、好
ましくない事態を招来するおそれがあり、安定性に大き
な問題を有している。[0005] On the other hand, steroids exhibit a sufficient anti-inflammatory effect, but after repeated use, a rebound phenomenon may occur, which may lead to an undesirable situation, and has a serious problem in stability.
【0006】ところで、化粧料中に、従来知られている
L−アスコルビン酸誘導体を配合すると、保存安定性が
不充分であって、紫外線による炎症抑制効果及び美白効
果が充分に発揮されないことが多く、また、グリチルレ
チン類は、優れた抗炎症効果を示すものの、美白効果が
不充分であるなどの問題があった。By the way, when a conventionally known L-ascorbic acid derivative is blended into a cosmetic, the storage stability is insufficient, and the effect of suppressing inflammation and whitening by ultraviolet rays is often not sufficiently exhibited. In addition, glycyrrhetins have an excellent anti-inflammatory effect, but have a problem such as an insufficient whitening effect.
【0007】[0007]
【発明が解決しようとする課題】本発明は、このような
事情のもとで、皮膚に対して優れた美白効果と抗炎症効
果を有し、肌荒れを抑制するとともに、保存安定性や皮
膚安全性にも優れる皮膚用化粧料を提供することを目的
とするものである。SUMMARY OF THE INVENTION Under such circumstances, the present invention has an excellent whitening effect and anti-inflammatory effect on the skin, suppresses rough skin, and provides storage stability and skin safety. It is an object of the present invention to provide a skin cosmetic having excellent properties.
【0008】[0008]
【課題を解決するための手段】本発明者らは、前記の好
ましい性質を有する皮膚用化粧料を開発すべく鋭意研究
を重ねた結果、L−アスコルビン酸誘導体と抗炎症剤を
組み合わせて、化粧料中に配合することにより、その相
乗作用によって、従来それぞれの単独作用では得られな
かった効果が発揮され、紫外線などによって引き起こさ
れる皮膚の肌荒れに基づく色素沈着を抑制するととも
に、日焼けによる皮膚の黒色化や、シミ、ソバカスを防
止する上、保存安定性も良好となり、しかも皮膚安全性
に優れる化粧料が得られることを見出し、この知見に基
づいて本発明を完成するに至った。Means for Solving the Problems The inventors of the present invention have conducted intensive studies to develop a skin cosmetic having the above-mentioned preferable properties. As a result, a combination of an L-ascorbic acid derivative and an anti-inflammatory agent has been developed. By blending into the ingredients, the synergistic effect exerts an effect that could not be obtained by the conventional single action, suppresses pigmentation based on rough skin caused by ultraviolet rays etc., and blackens the skin due to sunburn The present inventors have found that cosmetics having good storage stability as well as excellent storage stability can be obtained in addition to preventing aging, spots, and freckles, and the present invention has been completed based on this finding.
【0009】すなわち、本発明は、(A)一般式(I)That is, the present invention relates to (A) a compound represented by the general formula (I)
【化2】 (式中、Rは炭素数1〜22のアルキル基である。)で
表されるL−アスコルビン酸誘導体と、(B)抗炎症剤
を含有することを特徴とする化粧料を提供するものであ
る。Embedded image (Wherein R is an alkyl group having 1 to 22 carbon atoms) and a cosmetic comprising (B) an anti-inflammatory agent. is there.
【0010】[0010]
【発明の実施の形態】本発明の化粧料においては、
(A)成分として、一般式(I)BEST MODE FOR CARRYING OUT THE INVENTION In the cosmetic of the present invention,
As the component (A), general formula (I)
【化3】 (式中、Rは炭素数1〜22のアルキル基である。)で
表されるL−アスコルビン酸誘導体が用いられる。Embedded image (In the formula, R is an alkyl group having 1 to 22 carbon atoms.) An L-ascorbic acid derivative represented by the following formula is used.
【0011】上記一般式(I)におけるRで示される炭
素数1〜22のアルキル基は直鎖状、分岐状、環状のい
ずれであってもよく、その例としてはメチル基、エチル
基、n−プロピル基、イソプロピル基、n−ブチル基、
イソブチル基、sec−ブチル基、tert−ブチル
基、ペンチル基、ヘキシル基、オクチル基、デシル基、
ドデシル基、テトラデシル基、ヘキサデシル基、オクタ
デシル基、ベヘニル基、シクロプロピル基、シクロブチ
ル基、シクロペンチル基、シクロヘキシル基、シクロオ
クチル基などが挙げられる。The alkyl group having 1 to 22 carbon atoms represented by R in the general formula (I) may be linear, branched, or cyclic, and examples thereof include a methyl group, an ethyl group, and an n group. -Propyl group, isopropyl group, n-butyl group,
Isobutyl group, sec-butyl group, tert-butyl group, pentyl group, hexyl group, octyl group, decyl group,
Dodecyl group, tetradecyl group, hexadecyl group, octadecyl group, behenyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cyclooctyl group and the like.
【0012】この一般式(I)で表されるL−アスコル
ビン酸誘導体は公知の化合物であって、例えば特開平8
−134055号公報記載の方法などに従って容易に製
造することができる。The L-ascorbic acid derivative represented by the general formula (I) is a known compound.
It can be easily produced according to the method described in JP-A-134055.
【0013】このL−アスコルビン酸誘導体はラジカル
消去能を有し、抗酸化物として用いられる。また、L−
アスコルビン酸や従来のL−アスコルビン酸誘導体に比
べて安定性に優れている点で有利である。This L-ascorbic acid derivative has a radical scavenging ability and is used as an antioxidant. Also, L-
This is advantageous in that it has superior stability as compared with ascorbic acid and conventional L-ascorbic acid derivatives.
【0014】本発明の化粧料においては、(A)成分と
して、前記一般式(I)で表されるL−アスコルビン酸
誘導体を1種用いてもよいし、2種以上組み合わせて用
いてもよいが、特に、効果おび安定性などの点から、R
がエチル基であるL−3−O−エチルアスコルビン酸が
好適である。In the cosmetic of the present invention, as the component (A), one kind of the L-ascorbic acid derivative represented by the above general formula (I) may be used, or two or more kinds may be used in combination. However, from the viewpoint of effect and stability,
Is an ethyl group, and L-3-O-ethylascorbic acid is preferred.
【0015】本発明の化粧料においては、(B)成分と
して抗炎症剤が用いられる。この抗炎症剤としては、グ
リチルレチン酸およびその誘導体が好適である。ここ
で、グリチルレチン酸誘導体としては、例えばグリチル
レチン酸三ナトリウム、グリチルレチン酸二カリウム、
グリチルレチン酸二ナトリウム、グリチルレチン酸モノ
アンモニウム、α−グリチルレチン酸モノアンモニウ
ム、β−グリチルレチン酸、グリチルレチン酸グリセリ
ン、グリチルレチン酸ステアリル、グリチルレチン酸ピ
リドキシンなどが挙げられるが、もちろんこれらに限定
されるものではない。In the cosmetic of the present invention, an anti-inflammatory agent is used as the component (B). Glycyrrhetinic acid and its derivatives are suitable as the anti-inflammatory agent. Here, as the glycyrrhetinic acid derivative, for example, trisodium glycyrrhetinate, dipotassium glycyrrhetinate,
Examples include, but are not limited to, disodium glycyrrhetinate, monoammonium glycyrrhetinate, monoammonium α-glycyrrhetinate, β-glycyrrhetinic acid, glyceryl glycyrrhetinate, stearyl glycyrrhetinate, pyridoxine glycyrrhetinate, and the like.
【0016】本発明においては、この(B)成分の抗炎
症剤は、1種用いてもよいし、2種以上を組み合わせて
用いてもよい。In the present invention, the anti-inflammatory component (B) may be used alone or in combination of two or more.
【0017】本発明の化粧料においては、前記(A)成
分のL−アスコルビン酸誘導体と(B)成分の抗炎症剤
の含有割合は、重量比で1:10〜10:1の範囲にあ
ることが重要である。この割合が上記範囲を逸脱すると
相乗効果が充分に発揮されず、本発明の目的が達せられ
ない。相乗効果を充分に発揮させ、美白効果、抗炎症効
果、皮膚に対する安全性及び保存安定性が高いレベルで
バランスした化粧料を得るには、この(A)成分と
(B)成分との割合は、重量比で1:8〜8:1の範囲
が好ましく、特に1:5〜5:1の範囲が好適である。In the cosmetic of the present invention, the content ratio of the L-ascorbic acid derivative of the component (A) and the anti-inflammatory agent of the component (B) is in the range of 1:10 to 10: 1 by weight. This is very important. If this ratio deviates from the above range, the synergistic effect is not sufficiently exhibited, and the object of the present invention cannot be achieved. In order to achieve a synergistic effect sufficiently and to obtain a cosmetic composition having a high level of whitening effect, anti-inflammatory effect, safety against skin and storage stability, the ratio of the components (A) and (B) is as follows: The weight ratio is preferably in the range of 1: 8 to 8: 1, and particularly preferably in the range of 1: 5 to 5: 1.
【0018】本発明の化粧料における前記(A)成分の
L−アスコルビン酸誘導体の含有量は、化粧料の形態に
応じて適宜選定されるが、一般的には、化粧料全量に基
づき、0.01〜10.0重量%の範囲で選ばれる。こ
の量が0.01重量%未満では美白効果が十分に発揮さ
れないおそれがあるし、10.0重量%を超えるとその
量の割には効果の向上が認められず、むしろ経済的に不
利となる。美白効果および経済性などを考慮すると、こ
のL−アスコルビン酸誘導体の含有量は、特に0.1〜
5.0重量%の範囲が好ましい。The content of the L-ascorbic acid derivative of the component (A) in the cosmetic of the present invention is appropriately selected according to the form of the cosmetic, but generally, it is 0 based on the total amount of the cosmetic. It is selected in the range of 0.01 to 10.0% by weight. If the amount is less than 0.01% by weight, the whitening effect may not be sufficiently exerted. If the amount is more than 10.0% by weight, no improvement in the effect can be recognized for the amount. Become. In consideration of the whitening effect and the economical efficiency, the content of the L-ascorbic acid derivative is particularly preferably from 0.1 to
A range of 5.0% by weight is preferred.
【0019】また、本発明の化粧料における前記(B)
成分の抗炎症剤の含有量は、化粧料の形態に応じて適宜
選定されるが、抗炎症剤としてグリチルレチン酸やその
誘導体を用いる場合には、一般的には、化粧料全量に基
づき、0.01〜5.0重量%の範囲で選ばれる。この
量が0.01重量%未満では抗炎症効果が充分に発揮さ
れないおそれがあるし、5.0重量%を超えるとその量
の割には効果の向上が認められず、むしろ経済的に不利
となる。抗炎症効果および経済性などを考慮すると、こ
のグリチルレチン酸やその誘導体の含有量は、特に0.
1〜2.0重量%の範囲が好ましい。In the cosmetic of the present invention, the above (B)
The content of the component anti-inflammatory agent is appropriately selected according to the form of the cosmetic. However, when glycyrrhetinic acid or a derivative thereof is used as the anti-inflammatory agent, the content is generally 0 based on the total amount of the cosmetic. 0.01 to 5.0% by weight. If the amount is less than 0.01% by weight, the anti-inflammatory effect may not be sufficiently exerted. If the amount exceeds 5.0% by weight, no improvement in the effect is recognized for the amount, and it is economically disadvantageous. Becomes Considering the anti-inflammatory effect and the economical efficiency, the content of the glycyrrhetinic acid and its derivatives is particularly preferably 0.1%.
A range of 1 to 2.0% by weight is preferred.
【0020】本発明の化粧料には、前記必須成分以外
に、所望に応じ、従来皮膚用化粧料に慣用されている各
種成分、例えば保湿剤、動植物抽出物、多価アルコー
ル、低級アルコール、界面活性剤、乳化剤、乳化安定
剤、防腐防菌剤、香料、増粘剤、酸化防止剤、キレート
剤、pH調整剤、色素、紫外線吸収剤、紫外線散乱剤、
ビタミン類、アミノ酸類、他の美白剤、抗炎症剤、収斂
剤、水などを配合することができる。In the cosmetic of the present invention, in addition to the above essential components, various components conventionally used in skin cosmetics, such as humectants, animal and plant extracts, polyhydric alcohols, lower alcohols, Activator, emulsifier, emulsion stabilizer, antiseptic, antiseptic, perfume, thickener, antioxidant, chelating agent, pH adjuster, pigment, ultraviolet absorber, ultraviolet scattering agent,
Vitamins, amino acids, other whitening agents, anti-inflammatory agents, astringents, water and the like can be included.
【0021】前記保湿剤としては、例えばポリエチレン
グリコールやポリプロピレングリコールなどのポリエー
テル類、グリセリン、1,3−ブチレングリコール、プ
ロピレングリコール、ソルビトールなどの多価アルコー
ル類、さらにはNMF(天然保湿因子)類、具体的には
アミノ酸、尿素、乳酸ナトリウム、ピロリドンカルボン
酸ナトリウムや、ヒアルロン酸、コンドロイチン硫酸な
どのムコ多糖類、コラーゲンやエラスチンなどのタンパ
ク質などが挙げられる。Examples of the humectant include polyethers such as polyethylene glycol and polypropylene glycol, polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol and sorbitol, and NMF (natural humectant). Specific examples include amino acids, urea, sodium lactate, sodium pyrrolidonecarboxylate, mucopolysaccharides such as hyaluronic acid and chondroitin sulfate, and proteins such as collagen and elastin.
【0022】油分としては、例えばヒマシ油、オリーブ
油、ホホバ油、椿油などの液体油脂、硬化ヒマシ油など
の固体油脂、ラノリン、鯨ロウ、蜜ロウ、カルナウバロ
ウ、キャンデリラロウなどのロウ類、スクワラン、ワセ
リン、流動パラフィン、セリシン、パラフィンなどの炭
化水素類などが挙げられる。Examples of the oil component include liquid oils such as castor oil, olive oil, jojoba oil and camellia oil, solid oils such as hardened castor oil, waxes such as lanolin, spermaceti, beeswax, carnauba wax, candelilla wax, squalane, Examples include hydrocarbons such as petrolatum, liquid paraffin, sericin, and paraffin.
【0023】多価アルコールとしては、例えばグリセリ
ン、ポリグリセリン、トリメチロールプロパン、ペンタ
エリスリトール、ジペンタエリスリトール、エチレング
リコール、プロピレングリコール、ポリプロピレングリ
コール、1,3−ブチレングリコール、1,4−ブチレ
ングリコール、さらにはグルコース、マルトース、マン
ノース、ラクトース、D−グルクロン酸、ウロン酸、サ
ッカロース、D−マンニット、D−ソルビット、ソルビ
タン、グルコラクトン、セルロース、デンプン、アルブ
チン、グルコースリン酸エステルなどの単糖類、多糖類
及びこれらの誘導体などが挙げられる。また、低級アル
コールとしては、例えばエチルアルコール、プロピルア
ルコール、イソプロピルアルコールなどが挙げられる。Examples of polyhydric alcohols include glycerin, polyglycerin, trimethylolpropane, pentaerythritol, dipentaerythritol, ethylene glycol, propylene glycol, polypropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, and the like. Are glucose, maltose, mannose, lactose, D-glucuronic acid, uronic acid, saccharose, D-mannitol, D-sorbitol, sorbitan, glucolactone, cellulose, starch, arbutin, monosaccharides such as glucose phosphate, and polysaccharides And their derivatives. Examples of the lower alcohol include ethyl alcohol, propyl alcohol, and isopropyl alcohol.
【0024】界面活性剤としては、例えばポリオキシエ
チレン(POE)ソルビタンモノオレエートなどのPO
Eソルビタンエステル、ソルビタンモノオレエートなど
のソルビタンエステル、POE−グリセリルモノオレエ
ートなどのPOE−グリセリン脂肪酸エステル、グリセ
リンモノオレエートなどのグリセリン脂肪酸エステル、
POE−モノオレエートなどのPOE−脂肪酸エステ
ル、POE−ラウリルエーテルなどのPOE−アルキル
エーテル、POE−オクチルドデシルエーテルなどのP
OE−分岐アルキルエーテル、POE−ノニルフェニル
エーテルなどのPOE−アルキルフェニルエーテル、グ
リセロールモノイソステアレートなどのグリセロールエ
ステル、POE−グリセロールモノイソステアレートな
どのPOE−グリセロールエステル、ジグリセリルモノ
ステアレートなどのポリグリセリン脂肪酸エステルなど
の非イオン性界面活性剤、ステアリン酸などの高級脂肪
酸のナトリウム塩やカリウム塩などの脂肪酸石ケン、ラ
ウリル硫酸ナトリウムなどの高級アルキル硫酸エステル
塩、POE−ラウリル硫酸トリエタノールアミンなどの
アルキルエーテル硫酸エステル、ラウロイルサルコシン
ナトリウムなどのN−アシルサルコシン酸塩、N−ミリ
ストイル−N−メチルタウリンナトリウムなどの高級脂
肪酸アミドスルホン酸塩、リニアドデシルベンゼンスル
ホン酸ナトリウムなどのアルキルベンゼンスルホン酸ナ
トリウム、N−ステアロイルグルタミン酸ジナトリウム
などのN−アシルグルタミン酸塩などの陰イオン性界面
活性剤、アルキルアミン塩、POE−アルキルアミン
塩、ポリアミン脂肪酸誘導体、アルキルピリジニウム
塩、アルキル四級アンモニウム塩、アルキルジメチルベ
ンジルアンモニウム塩、アルキルイソキノリニウム塩、
ジアルキルモリホニウム塩、塩化ベンゼトニウムなどの
陽イオン性界面活性剤、ベタイン系、イミダゾリン系、
アミンオキシド系などの両性界面活性剤が挙げられる。As the surfactant, for example, a polyoxyethylene (POE) sorbitan monooleate or the like
E sorbitan esters, sorbitan esters such as sorbitan monooleate, POE-glycerin fatty acid esters such as POE-glyceryl monooleate, glycerin fatty acid esters such as glycerin monooleate,
POE-fatty acid esters such as POE-monooleate; POE-alkyl ethers such as POE-lauryl ether; PEs such as POE-octyldodecyl ether;
OE-branched alkyl ethers, POE-alkyl phenyl ethers such as POE-nonylphenyl ether, glycerol esters such as glycerol monoisostearate, POE-glycerol esters such as POE-glycerol monoisostearate, diglyceryl monostearate and the like. Nonionic surfactants such as polyglycerin fatty acid esters, fatty acid soaps such as sodium and potassium salts of higher fatty acids such as stearic acid, higher alkyl sulfates such as sodium lauryl sulfate, POE-lauryl sulfate triethanolamine, etc. Alkyl ether sulfates, N-acyl sarcosine salts such as sodium lauroyl sarcosine, and higher fatty acid amide sulfo such as N-myristoyl-N-methyltaurine sodium. Acid salts, anionic surfactants such as sodium alkylbenzenesulfonate such as sodium linear dodecylbenzenesulfonate, N-acyl glutamates such as disodium N-stearoylglutamate, alkylamine salts, POE-alkylamine salts, polyamine fatty acids Derivatives, alkylpyridinium salts, alkyl quaternary ammonium salts, alkyldimethylbenzylammonium salts, alkylisoquinolinium salts,
Cationic surfactants such as dialkyl morphonium salts and benzethonium chloride, betaines, imidazolines,
Examples include amphoteric surfactants such as amine oxides.
【0025】乳化剤としては、例えばグリセリン脂肪酸
エステル、ソルビタン脂肪酸エステル、プロピレングリ
コール脂肪酸エステル、大豆リン脂質などが挙げられ、
香料としては、例えば香精などの植物性天然香料、動物
性天然香料、合成香料などが挙げられる。Examples of the emulsifier include glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, and soybean phospholipid.
Examples of the flavor include plant natural flavors such as incense, animal natural flavors, and synthetic flavors.
【0026】防腐防菌剤としては、例えばp−ヒドロキ
シ安息香酸メチル、p−ヒドロキシ安息香酸エチル、デ
ヒドロ酢酸、サリチル酸、安息香酸、ソルビン酸、塩化
ベンザルコニウムなどが挙げられ、増粘剤としては、例
えばアルギン酸ナトリウム、キサンタンガム、ケイ酸ア
ルミニウム、マロメロ種子抽出物、トラガントガム、デ
ンプンなどの天然高分子物質、メチルセルロース、ヒド
ロキシエチルセルロース、カルボキシメチルセルロー
ス、可溶性デンプン、カチオン化セルロースなどの半合
成高分子物質、カルボキシビニルポリマー、ポリビニル
アルコールなどの合成高分子物質などが挙げられる。Examples of the antiseptic / antibacterial agent include methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, dehydroacetic acid, salicylic acid, benzoic acid, sorbic acid, and benzalkonium chloride. For example, natural polymer substances such as sodium alginate, xanthan gum, aluminum silicate, malomelo seed extract, tragacanth gum, starch, semi-synthetic polymer substances such as methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, soluble starch, cationized cellulose, carboxyvinyl Examples of the polymer include synthetic polymers such as polymers and polyvinyl alcohol.
【0027】また、酸化防止剤としては、例えばジブチ
ルヒドロキシトルエン、ブチルヒドロキシアニソール、
没食子酸プロピル、アスコルビン酸などが、キレート剤
としては、例えばエデト酸二ナトリウム、エタンヒドロ
キシジホスフェート、ピロリン酸塩、ヘキサメタリン酸
塩、クエン酸、酒石酸、グルコン酸などが、pH調整剤
としては、例えば水酸化ナトリウム、トリエタノールア
ミン、クエン酸、クエン酸ナトリウム、ホウ酸、ホウ
砂、リン酸一水素ナトリウムなどが挙げられる。As the antioxidant, for example, dibutylhydroxytoluene, butylhydroxyanisole,
As propyl gallate, ascorbic acid, etc., as chelating agents, for example, disodium edetate, ethanehydroxydiphosphate, pyrophosphate, hexametaphosphate, citric acid, tartaric acid, gluconic acid, etc., as a pH adjuster, Examples include sodium hydroxide, triethanolamine, citric acid, sodium citrate, boric acid, borax, sodium hydrogen phosphate and the like.
【0028】さらに、紫外線吸収剤としては、例えば2
−ヒドロキシ−4−メトキシベンゾフェノン、オクチル
ジメチルp−アミノベンゾエート、エチルヘキシルp−
メトキシシンナメートなどが、紫外線散乱剤としては、
例えば酸化チタン、カオリン、タルクなどが、ビタミン
類としては、例えばビタミンA、ビタミンB、ビタミン
C、ビタミンD、ビタミンE、ビタミンF、ビタミン
K、ビタミンP、ビタミンU、カルニチン、フェルラ
酸、α−オリザノール、α−リボ酸、オロット酸及びそ
の誘導体などが、アミノ酸類としては、例えばグリシ
ン、アラニン、バリン、ロイシン、イソロイシン、セリ
ン、トレオニン、フェニルアラニン、チロシン、トリプ
トファン、シスチン、システイン、メチオニン、プロリ
ン、ヒドロキシプロリン、アスパラギン酸、グルタミン
酸、アルギニン、ヒスチジン、リジン及びこれらの誘導
体などが挙げられる。Further, as the ultraviolet absorber, for example, 2
-Hydroxy-4-methoxybenzophenone, octyldimethyl p-aminobenzoate, ethylhexyl p-
Methoxy cinnamate and the like, as an ultraviolet scattering agent,
For example, titanium oxide, kaolin, talc and the like, and vitamins such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin F, vitamin K, vitamin P, vitamin U, carnitine, ferulic acid, α- Oryzanol, α-riboic acid, orotic acid and derivatives thereof include amino acids such as glycine, alanine, valine, leucine, isoleucine, serine, threonine, phenylalanine, tyrosine, tryptophan, cystine, cysteine, methionine, proline, and hydroxy. Examples include proline, aspartic acid, glutamic acid, arginine, histidine, lysine and derivatives thereof.
【0029】他の美白剤としては、例えばアルブチン、
コウジ酸、グラブリジン、プラセンタエキス、エラグ酸
などが挙げられる。Other whitening agents include, for example, arbutin,
Kojic acid, glabridine, placenta extract, ellagic acid and the like can be mentioned.
【0030】本発明の化粧料は、前記(A)成分のL−
アスコルビン酸誘導体、(B)成分の抗炎症剤およびこ
れらの任意成分を、公知の方法に従って適当に配合する
ことにより、化粧水、乳液、クリーム、パック剤、パウ
ダー、スプレー、軟膏、分散液、洗浄料など、種々の皮
膚用製品形態として用いることができる。The cosmetic of the present invention comprises the component (A) L-
By appropriately mixing the ascorbic acid derivative, the anti-inflammatory agent of the component (B) and these optional components according to a known method, lotion, emulsion, cream, pack, powder, spray, ointment, dispersion, washing It can be used as various skin product forms such as ingredients.
【0031】例えば、乳液などの場合、油相および水相
をそれぞれ加熱溶解したものを混合し、乳化分散させて
冷却する通常の方法により調製することができる。For example, in the case of an emulsion, it can be prepared by a usual method in which an oil phase and an aqueous phase, each of which is dissolved by heating, are mixed, emulsified and dispersed, and cooled.
【0032】[0032]
【実施例】次に、本発明を実施例により、さらに詳細に
説明するが、本発明は、これらの例によってなんら限定
されるものではない。Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
【0033】 実施例1 化粧水の調製 (重量%) (a) グリチルレチン酸 1.0 (b) L−3−O−エチルアスコルビン酸 2.0 (c) グリセリン 5.0 (d) ポリオキシエチレンソルビタンモノラウレート(2OE.O.)1.0 (e) エタノール 6.0 (f) 香料 適量 (g) 防腐剤・酸化防止剤 適量 (h) 精製水 残部 合計 100.0 上記(a)〜(h)成分を混合して均一に溶解することによ
り、化粧水を調製した。Example 1 Preparation of lotion (% by weight) (a) Glycyrrhetinic acid 1.0 (b) L-3-O-ethylascorbic acid 2.0 (c) Glycerin 5.0 (d) Polyoxyethylene Sorbitan monolaurate (2OE.O.) 1.0 (e) Ethanol 6.0 (f) Perfume proper amount (g) Preservative / antioxidant proper amount (h) Purified water Remainder 100.0 Above (a)- (h) A lotion was prepared by mixing and uniformly dissolving the components.
【0034】 実施例2 乳液の調製 (重量%) (a) ミツロウ 0.5 (b) ワセリン 2.0 (c) スクワラン 8.0 (d) ソルビタンセスキオレエート 0.8 (e) ポリオキシエチレンオレイルエーテル(2OE.O.) 1.2 (f) β−グリチルレチン酸 0.5 (g) 1,3−ブチレングリコール 7.0 (h) カルボキシビニルポリマー 0.2 (i) 水酸化カリウム 0.1 (j) 精製水 残部 (k) 防腐剤・酸化防止剤 適量 (l) L−3−O−エチルアスコルビン酸 2.0 (m) エタノール 7.0 合計 100.0 まず、上記(a)〜(e)成分を加熱溶解し、80℃に保持
した。一方、(g)〜(l)成分を加熱溶解し、80℃に保
ち、上記(a)〜(e)成分に加えて、乳化し、50℃まで
撹拌しながら冷却したのち、これに、50℃で(f)およ
び(m)成分を添加し、40℃まで冷却することにより、
乳液を調製した。Example 2 Preparation of emulsion (% by weight) (a) Beeswax 0.5 (b) Vaseline 2.0 (c) Squalane 8.0 (d) Sorbitan sesquioleate 0.8 (e) Polyoxyethylene Oleyl ether (2OE.O.) 1.2 (f) β-glycyrrhetinic acid 0.5 (g) 1,3-butylene glycol 7.0 (h) Carboxyvinyl polymer 0.2 (i) Potassium hydroxide 0. 1 (j) Purified water Remainder (k) Preservative / antioxidant appropriate amount (l) L-3-O-ethylascorbic acid 2.0 (m) Ethanol 7.0 Total 100.0 First, the above (a)- The component (e) was dissolved by heating and kept at 80 ° C. On the other hand, the components (g) to (l) are dissolved by heating, kept at 80 ° C., added to the components (a) to (e), emulsified, and cooled while stirring to 50 ° C. C. by adding (f) and (m) components and cooling to 40 ° C.
An emulsion was prepared.
【0035】 実施例3 化粧用クレームの調製 (重量%) (a) ミツロウ 2.0 (b) ステアリルアルコール 5.0 (c) ステアリン酸 8.0 (d) スクワラン 10.0 (e) 自己乳化型グリセリルモノステアレート 3.0 (f) ポリオキシエチレンセチルエーテル(2OE.O.) 1.0 (g) グリチルレチン酸 1.0 (h) 1,3−ブチレングリコール 5.0 (i) 水酸化カリウム 0.3 (j) 防腐剤・酸化防止剤 適量 (k) L−3−O−エチルアスコルビン酸 1.0 (l) 精製水 残部 合計 100.0 まず、上記(a)〜(f)成分を加熱溶解して、80℃に保
持した。一方、(g)〜(l)成分を加熱溶解して80℃に
保ち、これを上記(a)〜(f)成分に加えて乳化したの
ち、40℃まで撹拌しながら乳化することにより、化粧
用クリームを調製した。Example 3 Preparation of cosmetic claim (% by weight) (a) Beeswax 2.0 (b) Stearyl alcohol 5.0 (c) Stearic acid 8.0 (d) Squalane 10.0 (e) Self-emulsifying Glyceryl monostearate 3.0 (f) Polyoxyethylene cetyl ether (2OE.O.) 1.0 (g) Glycyrrhetinic acid 1.0 (h) 1,3-butylene glycol 5.0 (i) Hydroxide Potassium 0.3 (j) Preservative / antioxidant appropriate amount (k) L-3-O-ethylascorbic acid 1.0 (l) Purified water Remainder 100.0 First, the above components (a) to (f) Was heated and dissolved, and kept at 80 ° C. On the other hand, the components (g) to (l) are heated and dissolved and kept at 80 ° C., and then added to the components (a) to (f) to emulsify the mixture. A cream for use was prepared.
【0036】 実施例4 パック剤の調製 (重量%) (a) グリチルレチン酸二カリウム 1.0 (b) 酢酸ビニル樹脂エマルジョン 15.0 (c) ポリビニルアルコール 10.0 (d) オリーブ油 3.0 (e) L−3−O−エチルアスコルビン酸 2.0 (f) グリセリン 5.0 (g) 酸化チタン 8.0 (h) カオリン 7.0 (i) エタノール 8.0 (j) 香料 適量 (k) 防腐剤・酸化防止剤 適量 (l) 精製水 残部 合計 100.0 まず、上記(a)〜(l)成分を混合し、よく撹拌、分散さ
せ、均質化することにより、パック剤を調製した。前記
実施例1〜4で調製した各化粧料は、温度40℃におい
て3ケ月間放置しても、着色、沈殿などの生成は認めら
れず、配合したL−アスコルビン酸誘導体も安定であっ
た。Example 4 Preparation of Packing Agent (% by Weight) (a) Dipotassium glycyrrhetinate 1.0 (b) Vinyl acetate resin emulsion 15.0 (c) Polyvinyl alcohol 10.0 (d) Olive oil 3.0 ( e) L-3-O-ethylascorbic acid 2.0 (f) Glycerin 5.0 (g) Titanium oxide 8.0 (h) Kaolin 7.0 (i) Ethanol 8.0 (j) Fragrance Appropriate amount (k Preservative / Antioxidant Appropriate amount (l) Purified water Remainder 100.0 First, the above components (a) to (l) were mixed, well stirred, dispersed, and homogenized to prepare a pack. . Even when the cosmetics prepared in Examples 1 to 4 were left at a temperature of 40 ° C. for 3 months, generation of coloring, precipitation, and the like was not observed, and the compounded L-ascorbic acid derivative was stable.
【0037】実施例5 乳液の調製 実施例2において、β−グリチルレチン酸の量を0.5
重量%から1.0重量%に変えた以外は、実施例2と同
様にして乳液を調製した。Example 5 Preparation of emulsion In Example 2, the amount of β-glycyrrhetinic acid was 0.5
An emulsion was prepared in the same manner as in Example 2, except that the weight% was changed to 1.0% by weight.
【0038】比較例1 乳液の調製 実施例2において、β−グリチルレチン酸を用いなかっ
たこと以外は、実施例2と同様にして乳液を調製した。Comparative Example 1 Preparation of Emulsion An emulsion was prepared in the same manner as in Example 2 except that β-glycyrrhetinic acid was not used.
【0039】比較例2 乳液の調製 実施例2において、L−3−O−エチルアスコルビン酸
を用いないで、かつβ−グリチルレチン酸の量を0.5
重量%から1.0重量%に変えた以外は、実施例2と同
様にして乳液を調製した。Comparative Example 2 Preparation of Emulsion In Example 2, L-3-O-ethylascorbic acid was not used and the amount of β-glycyrrhetinic acid was 0.5
An emulsion was prepared in the same manner as in Example 2, except that the weight% was changed to 1.0% by weight.
【0040】比較例3 乳液の調製 実施例2において、L−3−O−エチルアスコルビン酸
2.0重量%の代わりに、安定な美白成分として周知の
L−アスコルビン酸二硫酸2.0重量%を用い、かつβ
−グリチルレチン酸の量を0.5重量%から1.0重量
%に変えた以外は、実施例2と同様にして乳液を調製し
た。COMPARATIVE EXAMPLE 3 Preparation of Emulsion In Example 2, 2.0% by weight of L-ascorbic acid disulfuric acid, which is well known as a stable whitening ingredient, is replaced by 2.0% by weight of L-3-O-ethylascorbic acid. And β
-An emulsion was prepared in the same manner as in Example 2, except that the amount of glycyrrhetinic acid was changed from 0.5% by weight to 1.0% by weight.
【0041】試験例 実施例5および比較例1〜3で調製した乳液について、
以下に示すテストを行い、美白効果と肌荒れ改善効果を
評価した。その結果を表1に示す。 〈使用テスト〉30〜50才の20名の女性をパネラー
とし、毎日朝と夜の2回、3ケ月間にわたり洗顔後に試
験乳液を顔面に塗布し、下記の基準に従って、美白効果
および肌荒れ改善効果を評価した。 (1) 美白効果評価基準 ・有効 :シミ、ソバカスが目立たなくなった。 ・やや有効:シミ、ソバカスがあまり目立たなくなっ
た。 ・無効 :変わらない。 (2) 肌荒れ改善効果評価基準 ・有効 :肌の荒れ、かさつきがなくなった。 ・やや有効:肌の荒れ、かさつきが少なくなった。 ・無効 :変わらない。Test Example The emulsions prepared in Example 5 and Comparative Examples 1 to 3
The following tests were performed to evaluate the whitening effect and the effect of improving skin roughness. Table 1 shows the results. <Usage test> Twenty women aged 30 to 50 were used as panelists, and the test emulsion was applied to the face twice a day for three months after washing the face twice a day in the morning and evening. Was evaluated. (1) Whitening effect evaluation criteria-Effective: spots and freckles became less noticeable.・ Slightly effective: spots and freckles are less noticeable. -Invalid: No change. (2) Evaluation criteria for improving skin roughness ・ Effective: Skin roughness and bulkiness are eliminated. -Slightly effective: less rough skin and less bulk. -Invalid: No change.
【0042】[0042]
【表1】 [Table 1]
【0043】表1から明らかなように、実施例5の乳液
は、皮膚の美白効果および肌荒れ改善効果に対して有効
であった。As is clear from Table 1, the emulsion of Example 5 was effective for the skin whitening effect and the skin roughness improving effect.
【0044】[0044]
【発明の効果】本発明の皮膚用化粧料は、紫外線などに
よって引き起こされる皮膚の肌荒れに基づく色素沈着を
抑制するとともに、日焼けによる皮膚の黒色化や、シ
ミ、ソバカスを防止する上、保存安定性および皮膚安全
性にも優れ、安心して使用することができる。EFFECTS OF THE INVENTION The skin cosmetic of the present invention suppresses pigmentation due to rough skin caused by ultraviolet rays, prevents blackening of the skin due to sunburn, spots, freckles, and storage stability. It is also excellent in skin safety and can be used with confidence.
Claims (4)
表されるL−アスコルビン酸誘導体と、(B)抗炎症剤
を含有することを特徴とする化粧料。(A) General formula (I) (Wherein, R is an alkyl group having 1 to 22 carbon atoms). A cosmetic comprising an L-ascorbic acid derivative represented by the formula (B) and an anti-inflammatory agent (B).
が、一般式(I)におけるRがエチル基のL−3−O−
エチルアスコルビン酸である請求項1に記載の化粧料。2. The L-ascorbic acid derivative of the component (A) is a compound of the formula (I) wherein R is an ethyl-3-L-O-.
The cosmetic according to claim 1, which is ethyl ascorbic acid.
ン酸およびその誘導体の中から選ばれる少なくとも1種
である請求項1または2に記載の化粧料。3. The cosmetic according to claim 1, wherein the anti-inflammatory component (B) is at least one selected from glycyrrhetinic acid and derivatives thereof.
が、重量比で1:10〜10:1の範囲にある請求項
1、2または3に記載の化粧料。4. The cosmetic according to claim 1, wherein the content ratio of the component (A) to the component (B) is in the range of 1:10 to 10: 1 by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19398A JPH11199426A (en) | 1998-01-05 | 1998-01-05 | Cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19398A JPH11199426A (en) | 1998-01-05 | 1998-01-05 | Cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11199426A true JPH11199426A (en) | 1999-07-27 |
Family
ID=11467170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19398A Pending JPH11199426A (en) | 1998-01-05 | 1998-01-05 | Cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH11199426A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001089357A (en) * | 1999-09-24 | 2001-04-03 | Alron Japan Inc | Method for releasing l-ascorbic acid, l-ascorbic acid derivative and/or l-ascorbic acid-containing extract to dermic layer of skin and composition therefor |
| JP2002047182A (en) * | 2000-08-02 | 2002-02-12 | Ito Keiko | Composition for external application for improving fur quality of pet |
| JP2002284666A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
| JP2002284626A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | External skin preparation |
| JP2002284623A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
| WO2009145300A1 (en) * | 2008-05-29 | 2009-12-03 | 株式会社資生堂 | External preparation for skin |
| JP2014520166A (en) * | 2012-06-29 | 2014-08-21 | バイオスペクトラム アイエヌシー | Skin whitening composition containing Madecasoside |
| JP2015028007A (en) * | 2013-07-05 | 2015-02-12 | 富士フイルム株式会社 | Dihydrotestosterone-induced interleukin production inhibitor |
| US10322078B2 (en) | 2014-06-10 | 2019-06-18 | Ajinomoto Co., Inc. | Cosmetic composition containing 3-O-alkyl-L-ascorbic acid or salt thereof |
| CN112351777A (en) * | 2018-06-28 | 2021-02-09 | 小林制药株式会社 | External composition |
| CN117398301A (en) * | 2023-11-29 | 2024-01-16 | 洛阳蓝斯利科技有限公司 | A method for preparing cosmetic with effects of keeping moisture, relieving and resisting allergy |
-
1998
- 1998-01-05 JP JP19398A patent/JPH11199426A/en active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001089357A (en) * | 1999-09-24 | 2001-04-03 | Alron Japan Inc | Method for releasing l-ascorbic acid, l-ascorbic acid derivative and/or l-ascorbic acid-containing extract to dermic layer of skin and composition therefor |
| JP2002047182A (en) * | 2000-08-02 | 2002-02-12 | Ito Keiko | Composition for external application for improving fur quality of pet |
| JP2002284666A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
| JP2002284626A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | External skin preparation |
| JP2002284623A (en) * | 2001-03-23 | 2002-10-03 | Nippon Hypox Lab Inc | Cosmetics |
| JP5553411B2 (en) * | 2008-05-29 | 2014-07-16 | 株式会社 資生堂 | Skin preparation |
| WO2009145300A1 (en) * | 2008-05-29 | 2009-12-03 | 株式会社資生堂 | External preparation for skin |
| KR101455969B1 (en) * | 2008-05-29 | 2014-10-31 | 가부시키가이샤 시세이도 | External preparation for skin |
| JP2014520166A (en) * | 2012-06-29 | 2014-08-21 | バイオスペクトラム アイエヌシー | Skin whitening composition containing Madecasoside |
| JP2015028007A (en) * | 2013-07-05 | 2015-02-12 | 富士フイルム株式会社 | Dihydrotestosterone-induced interleukin production inhibitor |
| US10322078B2 (en) | 2014-06-10 | 2019-06-18 | Ajinomoto Co., Inc. | Cosmetic composition containing 3-O-alkyl-L-ascorbic acid or salt thereof |
| CN112351777A (en) * | 2018-06-28 | 2021-02-09 | 小林制药株式会社 | External composition |
| CN112351777B (en) * | 2018-06-28 | 2024-10-18 | 小林制药株式会社 | Composition for external use |
| US12396978B2 (en) | 2018-06-28 | 2025-08-26 | Kobayashi Pharmaceutical Co., Ltd. | External-use composition |
| CN117398301A (en) * | 2023-11-29 | 2024-01-16 | 洛阳蓝斯利科技有限公司 | A method for preparing cosmetic with effects of keeping moisture, relieving and resisting allergy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0552806B2 (en) | ||
| JPH11199426A (en) | Cosmetic | |
| JPH11255638A (en) | Tyrosinase activity inhibitor and cosmetic | |
| JP2000247893A (en) | Antimicrobial agent, bathing agent composition and skin cleansing agent composition | |
| KR102463133B1 (en) | Cosmetic Composition Containing High-Content of Urea | |
| JP2003306419A (en) | Cosmetic | |
| JPH05271046A (en) | Dermal medicine for external use | |
| JPH09291016A (en) | Hair cosmetic material | |
| JP2003012498A (en) | Composition for external use | |
| KR950007906B1 (en) | Long wave uv ray absorber and its cosmetics | |
| JP2780803B2 (en) | External preparation for skin | |
| JPH11269034A (en) | Skin prepafation for external use for improving acne | |
| JPH11199425A (en) | Cosmetic | |
| JPH1072330A (en) | Tyrosinase activity inhibitor and cosmetic | |
| JPH0196109A (en) | whitening cosmetics | |
| JP2003277261A (en) | External preparation for skin | |
| JPH11292752A (en) | Whitening agent and skin external composition | |
| JP2786233B2 (en) | External preparation for skin | |
| JP2000212057A (en) | Cosmetic composition | |
| JPH10182404A (en) | Preparation for external use for skin | |
| JP2003252718A (en) | In vivo dihydroxyindole compound polymerization inhibitor | |
| EP0344708A2 (en) | Composition for external application to skin | |
| JP2753639B2 (en) | Cosmetics | |
| JPH02231408A (en) | Novel skin drug for external use | |
| JPH01100112A (en) | External preparation for skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20031030 |